DeepMed Research

AHS Cancer Control Alberta

🇨🇦Canada

Country: 🇨🇦Canada

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)

Phase 2

Not yet recruiting

Conditions: Immune-related Adverse Event
Diarrhea
Advanced Rectal Carcinoma
Advanced Melanoma

Interventions: Drug: Mesalamine

First Posted Date: 2022-12-23

Last Posted Date: 2024-06-12

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 20

Registration Number: NCT05663775

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

BIOmarker-guided Study to Evaluate the Efficacy and Safety of cemipLimab for advancEd Cutaneous T-cell Lymphoma

Phase 1

Not yet recruiting

Conditions: Mycosis Fungoides

Interventions: Drug: Cemiplimab

First Posted Date: 2022-09-14

Last Posted Date: 2024-06-14

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 16

Registration Number: NCT05538988

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Participating in Tai Chi to Reduce Anxiety and Keep up Physical Function

Not Applicable

Active, not recruiting

Conditions: Prostate Cancer

Interventions: Other: Tai Chi Prehabilitation
Other: Usual care

First Posted Date: 2022-07-11

Last Posted Date: 2024-01-30

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 40

Registration Number: NCT05452824

Locations: 🇨🇦
Prostate Cancer Centre, Calgary, Alberta, Canada

Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)

Phase 2

Recruiting

Conditions: Pancreatic Cancer
Hepatocellular Cancer
Biliary Tract Cancer
Cholangiocarcinoma

Interventions: Biological: Durvalumab
Drug: Gemcitabine
Drug: Nab paclitaxel
Biological: Tremelimumab
Drug: Propranolol
Drug: Cisplatin

First Posted Date: 2022-07-11

Last Posted Date: 2024-06-12

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 62

Registration Number: NCT05451043

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Pilot Trial for Treatment of Recurrent Glioblastoma

Early Phase 1

Recruiting

Conditions: Recurrent Glioblastoma
Glioblastoma
Recurrent Disease

Interventions: Drug: Afatinib
Drug: Dasatinib
Drug: Palbociclib
Drug: Everolimus
Drug: Olaparib

First Posted Date: 2022-06-27

Last Posted Date: 2025-04-25

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 10

Registration Number: NCT05432518

Locations: 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

Loratadine for the Prevention of G-CSF-related Bone Pain

Phase 2

Recruiting

Conditions: Stem Cell Transplant Complications

Interventions: Drug: Placebo
Drug: Loratadine

First Posted Date: 2022-06-16

Last Posted Date: 2025-01-29

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 78

Registration Number: NCT05421416

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Northern Alberta Linac-MR Image-Guided Radiotherapy (Northern LIGHTs-2)

Phase 1

Recruiting

Conditions: Cancer

Interventions: Device: MR guided radiotherapy

First Posted Date: 2022-06-10

Last Posted Date: 2024-01-30

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 112

Registration Number: NCT05413473

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery)

Phase 3

Recruiting

Conditions: Gynecologic Cancer
Iron-deficiency
Anemia

Interventions: Drug: Ferric derisomaltose
Drug: Placebo

First Posted Date: 2022-06-07

Last Posted Date: 2025-04-25

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 82

Registration Number: NCT05407987

Locations: 🇨🇦
Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

Nutritional Supplementation in Head and Neck Cancers

Phase 2

Recruiting

Conditions: Nutritional Deficiency
Malnourishment
Undernutrition

Interventions: Other: Resource® Support Plus

First Posted Date: 2022-05-18

Last Posted Date: 2025-03-28

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 81

Registration Number: NCT05379712

Locations: 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada

A Study Involving Neoadjuvant Chemoradiotherapy with Hypofractionated Radiotherapy in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma

Not Applicable

Recruiting

Conditions: Esophageal Cancer

Interventions: Radiation: Hypofractionated radiotherapy

First Posted Date: 2022-05-11

Last Posted Date: 2024-11-18

Lead Sponsor: AHS Cancer Control Alberta

Target Recruit Count: 42

Registration Number: NCT05370144

Locations: 🇨🇦
Tom Baker Cancer Centre/Arthur J.E. Child Comprehensive Cancer Centre, Calgary, Alberta, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy